Skip to main content
Premium Trial:

Request an Annual Quote

Dutch Scientific Organization Subscribes to Celera s Database

NEW YORK, July 3 – The Netherlands Organization for Scientific Research has signed a multi-year subscription to Celera’s Discovery System genomic database and bioinformatics tools, Celera said Tuesday.

Under the terms of the deal, the Netherlands Organization, the leading Dutch organization for scientific research, can provide subscriptions to its publicly funded research institutions. Financial terms of the agreement were not disclosed. 

"We are pleased that the scientific community in the Netherlands recognizes the need for accurate genomic data and the tools and software to support their research projects, and through this agreement, has turned to Celera to provide this information," Craig Venter, Celera's president and chief scientific officer, said in a statement. 

"We look forward to working with the Dutch research community and aiding them in their quest toward a better understanding of human biology and disease,” he said.

Eduard Klasen, director of the Netherlands Organization for Scientific Research, said: "In the interest of the Dutch academic research in the Life Sciences, the Netherlands Organization of Scientific Research has decided to facilitate access for its academic research community to all relevant genomic data. We expect that the contract with Celera will further enhance the effectiveness of the recent and forthcoming Dutch funding programs in genomics and bioinformatics." 

The Netherlands Organization for Scientific Research has a budget of about 840 million Dutch guilders ($323.5 million) for 2001, or about five percent of the government’s investment in scientific research and development.

Celera has said in the past that academic subscribers generally pay between $7,000 and $15,000 a year per scientist for a subscription. 

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.